MedTech-related technology assessments and clinical guidelines from NICE in April 2022

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In April 2022, NICE published two new Interventional Procedures Guidance (IPG) and made the following conclusions:

• Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is inadequate in quantity and quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered with special arrangements for clinical governance, consent, and audit or research;
• Evidence on the efficacy and safety of liposuction for chronic lymphoedema is adequate. The evidence on safety shows that the potential risks include venous thromboembolism, fat embolism, and fluid overload. This procedure can be used with standard arrangements for clinical governance, consent, and audit.

One new clinical guideline on epilepsies in children, young people and adults was published in April 2022. NICE provides recommendations on epilepsy assessment and management, including the following topics:

• Assessment (e.g., neuroimaging, genetic testing, antibody testing);
• Referral to specialist services;
• Pharmacological and non-pharmacological treatments (e.g., resective epilepsy surgery, vagus nerve stimulation);
• And others.

One clinical guideline on diagnosis and initial management of stroke and transient ischaemic attack in over 16s was updated in April 2022. NICE reviewed the evidence and updated recommendations on blood pressure control for people with acute intracerebral hemorrhage.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).